In the third quarter, Generali Asset Management SPA SGR boosted its position in Illumina by 51.6%, acquiring an additional 7,574 shares to bring its total to 22,249 shares. According to the firm’s latest SEC filing, this purchase raised the value of its holdings in the life sciences company to approximately $2.11 million. This marked one of the largest single-quarter increases among institutional investors in Illumina, reflecting Generali’s heightened confidence in the company’s long-term growth prospects in genetic sequencing and diagnostic technologies.

Several prominent asset managers also adjusted their exposure to Illumina during the recent quarters. WCM Investment Management added 247,460 shares in the second quarter, bringing its total to 4.43 million shares valued at roughly $419.6 million. Loomis Sayles increased its stake by 78,317 shares to 4.23 million shares ($403.2 million), while AQR Capital Management expanded its position by 1.17 million shares, a 55.3% rise to 3.30 million shares ($313.3 million). Geode Capital and UBS AM also made modest increases, demonstrating that institutional ownership remains concentrated, with hedge funds and asset managers holding over 89% of the company’s outstanding shares.

On October 30th, Illumina reported third-quarter revenue of $1.08 billion, slightly above consensus estimates of $1.07 billion, and non-GAAP earnings per share of $1.34, beating analysts’ consensus by $0.18. The company achieved a 16.4% net margin and a return on equity of 29.2%. Year-over-year revenue growth was 0.4%, and management set full-year 2025 EPS guidance in the range of $4.65–$4.75, compared with the Street’s average forecast of $4.51. These results underline Illumina’s steady top-line performance despite continued macroeconomic headwinds in research spending.

During the fourth quarter, Director Scott Gottlieb purchased 500 shares at an average price of $122.13, increasing his stake by 4.2% to 12,523 shares, while CTO Scott M. Davies sold 323 shares at $136.09, reducing his holding by 1.8% to 17,887 shares. On the research front, five analysts upgraded Illumina to a buy or stronger rating this quarter, and Evercore ISI raised its price objective from $132 to $142. Conversely, Zacks Research downgraded the name to hold, and the consensus among 21 analysts remains a ‘hold’ with an average target of $118.31. These mixed signals illustrate a market divided on the company’s near-term valuation versus its long-term growth runway in genomics.